State Street

Court Grants Final Approval in General Electric ERISA Case

Retrieved on: 
Monday, March 11, 2024
Plan, Vexatious litigation, Retirement, Sale, District court, ERISA, State Street, Defendant, Settlement

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Judge Indira Talwani of the United States District Court for the District of Massachusetts has granted final approval of a $61 million cash settlement in IN RE: GE ERISA LITIGATION.

Key Points: 
  • BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Judge Indira Talwani of the United States District Court for the District of Massachusetts has granted final approval of a $61 million cash settlement in IN RE: GE ERISA LITIGATION.
  • Subsequently, other firms joined and co-litigated the matter on behalf of a nationwide class for almost 8 years through hard fought litigation and settlement.
  • “This is the largest settlement ever in an ERISA case alleging a retirement plan improperly offered proprietary funds.
  • “This was a long and hard-fought case and illustrates that Sanford Heisler Sharp will go the distance and is in these cases for the long haul,” Field said.

Scorpius Holdings, Inc. Announces Pricing of Public Offering

Retrieved on: 
Friday, March 8, 2024
ThinkEquity, Prospectus, Sale, Form, CDMO, State Street, S-3, Life insurance

DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses.

Key Points: 
  • DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $0.15 per share, for aggregate gross proceeds of $1,500,000, before deducting underwriting discounts, commissions and offering expenses.
  • The offering is expected to close on March 12, 2024, subject to satisfaction of customary closing conditions.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • A preliminary prospectus supplement and the accompanying base prospectus describing the terms of the offering was filed with the SEC on its website at www.sec.gov.

Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, March 7, 2024
ThinkEquity, S-3, CDMO, State Street, Sale, Form

DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering.

Key Points: 
  • DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced that it intends to offer to sell shares of its common stock to the public in an underwritten public offering.
  • All of the shares of common stock are to be sold by the Company.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • A preliminary prospectus supplement and the accompanying base prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov.

BioVie Inc. Announces Closing of Public Offering

Retrieved on: 
Wednesday, March 6, 2024
ThinkEquity, Prospectus, Liver disease, Sale, Form, State Street, S-3, Security (finance)

The gross proceeds to the Company from the offering are approximately $21,000,000, before deducting placement agent fees and offering expenses.

Key Points: 
  • The gross proceeds to the Company from the offering are approximately $21,000,000, before deducting placement agent fees and offering expenses.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • ThinkEquity acted as sole placement agent for the offering.
  • A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, March 5, 2024
Lexington Avenue, Telephone, Cantor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, Guggenheim Partners, Security (finance)

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.
  • All of the shares sold in the offering were sold by Celldex.
  • The gross proceeds to Celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.
  • Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as the joint bookrunning managers for the offering.

BioVie Inc. Announces Pricing of Public Offering

Retrieved on: 
Monday, March 4, 2024
ThinkEquity, Prospectus, Liver disease, Sale, Warrant, Form, State Street, S-3, Security (finance)

The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering expenses.

Key Points: 
  • The gross proceeds to the Company from the offering are expected to be approximately $21 million, before deducting placement agent fees and offering expenses.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.
  • The offering is expected to close on March 6, 2024, subject to satisfaction of customary closing conditions.
  • The offering will be made only by means of a written prospectus.

BioVie Inc. Announces Proposed Public Offering of Common Stoc

Retrieved on: 
Friday, March 1, 2024
ThinkEquity, Prospectus, Sale, Warrant, Form, State Street, S-3, Life insurance

All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.

Key Points: 
  • All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.
  • ThinkEquity LLC (“ThinkEquity”) is acting as sole placement agent for the offering.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024
Lexington Avenue, Prospectus, Telephone, Cantor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, S-3, Guggenheim Partners

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.
  • All of the shares to be sold in the offering are to be sold by Celldex.
  • In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses.

Presto Automation Announces Pricing of Approximately $2.1M Registered Direct Offering

Retrieved on: 
Thursday, February 29, 2024
SAN, Suite, Sale, Form, State Street, S-3, Security (finance), Presto

The offering is expected to close on or about March 4, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about March 4, 2024, subject to the satisfaction of customary closing conditions.
  • Chardan and Spartan are acting as joint placement agents for the offering.
  • The gross proceeds to Presto from this offering are expected to be approximately $2.1 million, before deducting Chardan and Spartan’s fees and other offering expenses payable by Presto.
  • Presto intends to use the net proceeds from this offering for working capital and general corporate purposes.

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, February 28, 2024
Lexington Avenue, Prospectus, Telephone, Sale, Form, State Street, SVB Securities, Therapy, S-3

HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering.

Key Points: 
  • HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an underwritten public offering.
  • Celldex expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock.
  • All of the shares of common stock are being offered by the Company.
  • Leerink Partners and TD Cowen are acting as the joint bookrunning managers for the proposed offering.